STI Stock Trade Intelligence
BDX

BCAL DIAGNOSTICS LIMITED

Health Care · ASX:BDX
$0.0600
0.00%
Market cap
$22M
Turnover
—
Last price
$0.0600
Day change
0.00%
Announcements
16
Range, past year
Open 0.087 · Low 0.052 · Now 0.060 · High 0.155
Open BDX in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.

BDX momentum and trend analysis

Our analysis
Independent analysis generated by Stock Trade Intelligence as at 2026-11-16.
Momentum quality
16/100
Wyckoff phase
Downtrend10d
Trend stage
Breakdown
1 Day
+0.0%
1 Week
-11.8%
1 Month
-24.1%
1 Year
-24.1%
RSI
36
Avg daily range
7.9%

BCAL DIAGNOSTICS LIMITED scores 16 out of 100 for momentum quality, a reading rated very low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Breakdown.

On the Wyckoff cycle it sits in Downtrend, where it has been for 10 trading days. The weekly timeframe reads Downtrend, which agrees with the daily view.

Against the wider market it is currently underperforming and the institutional accumulation signal reads low.

Points to watch
  • 60d drawdown -42.6%
  • High volatility (ATR 7.9%)
  • Risk rating: Very High
  • Composite downside risk elevated
Browse the whole market by signal:
ASX stocks in Wyckoff accumulationASX momentum stocks by trend qualityASX stocks breaking outASX stocks near 52-week highs

BDX announcements

Recent price-sensitive releases.
  • 2026-11-13 TOV: GSS - Panel Receives Application Scheme of Arrangement | Takeover - Other
  • 2026-10-30 Quarterly Activities/Appendix 4C Cash Flow Report Commitments Test Entity - First Quarter Activity Report | Commitments Test Entity - First Quarter Cashflow Report
  • 2026-09-30 BREASTESTplus 2 clinically validated Progress Report
  • 2026-09-23 BCAL Introduces Avantect Multi-Cancer Early Detection Test Progress Report
  • 2026-08-28 Appendix 4E and Annual Report to shareholders Annual Report | Top 20 shareholders | Preliminary Final Report | Full Year Accounts | Full Year Audit Review | Full Year Directors' Statement | Full Year Directors' Report
  • 2026-08-26 BCAL Takes Interest in Genetic Signatures to 18.46% Security holder details - Other
  • 2026-08-21 BCAL Secures Funding for FY2027 Update Periodic Reports - Other | Issued Capital - Other
Get the daily briefing The day's price-sensitive announcements, ranked by what actually moved, with our own momentum and cycle read on each.